BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38722446)

  • 1. The significance of partial volume effect on the estimation of hypoxic tumour volume with [
    Kafkaletos A; Mix M; Sachpazidis I; Carles M; Rühle A; Ruf J; Grosu AL; Nicolay NH; Baltas D
    EJNMMI Phys; 2024 May; 11(1):43. PubMed ID: 38722446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging.
    Löck S; Perrin R; Seidlitz A; Bandurska-Luque A; Zschaeck S; Zöphel K; Krause M; Steinbach J; Kotzerke J; Zips D; Troost EGC; Baumann M
    Radiother Oncol; 2017 Sep; 124(3):533-540. PubMed ID: 28843726
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Carles M; Fechter T; Grosu AL; Sörensen A; Thomann B; Stoian RG; Wiedenmann N; Rühle A; Zamboglou C; Ruf J; Martí-Bonmatí L; Baltas D; Mix M; Nicolay NH
    Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET.
    Wiedenmann N; Bunea H; Rischke HC; Bunea A; Majerus L; Bielak L; Protopopov A; Ludwig U; Büchert M; Stoykow C; Nicolay NH; Weber WA; Mix M; Meyer PT; Hennig J; Bock M; Grosu AL
    Radiat Oncol; 2018 Aug; 13(1):159. PubMed ID: 30157883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET measured hypoxia and MRI parameters in re-irradiated head and neck squamous cell carcinomas: findings of a prospective pilot study.
    Rogasch J; Beck M; Stromberger C; Hofheinz F; Ghadjar P; Wust P; Budach V; Amthauer H; Tinhofer I; Furth C; Walter-Rittel TC; Zschaeck S
    F1000Res; 2020; 9():1350. PubMed ID: 33796277
    [No Abstract]   [Full Text] [Related]  

  • 6. Geometric analysis of loco-regional recurrences in relation to pre-treatment hypoxia in patients with head and neck cancer.
    Boeke S; Thorwarth D; Mönnich D; Pfannenberg C; Reischl G; La Fougère C; Nikolaou K; Mauz PS; Paulsen F; Zips D; Welz S
    Acta Oncol; 2017 Nov; 56(11):1571-1576. PubMed ID: 28891398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between FMISO-PET based hypoxia in the primary tumour and in lymph node metastases in locally advanced HNSCC patients.
    Bandurska-Luque A; Löck S; Haase R; Richter C; Zöphel K; Perrin R; Appold S; Krause M; Steinbach J; Kotzerke J; Hofheinz F; Zips D; Baumann M; Troost EGC
    Clin Transl Radiat Oncol; 2019 Feb; 15():108-112. PubMed ID: 30834349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18F-FDG-PET partial volume effect correction using a modified recovery coefficient approach based on functional volume and local contrast: physical validation and clinical feasibility in oncology.
    Anouan KJ; Lelandais B; Edet-Sanson A; Ruan S; Vera P; Gardin I; Hapdey S
    Q J Nucl Med Mol Imaging; 2017 Sep; 61(3):301-313. PubMed ID: 26407135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy.
    Löck S; Linge A; Seidlitz A; Bandurska-Luque A; Nowak A; Gudziol V; Buchholz F; Aust DE; Baretton GB; Zöphel K; Steinbach J; Kotzerke J; Overgaard J; Zips D; Krause M; Baumann M; Troost EGC
    Radiother Oncol; 2019 Jun; 135():43-50. PubMed ID: 31015169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective Evaluation of a Tumor Control Probability Model Based on Dynamic
    Thorwarth D; Welz S; Mönnich D; Pfannenberg C; Nikolaou K; Reimold M; La Fougère C; Reischl G; Mauz PS; Paulsen F; Alber M; Belka C; Zips D
    J Nucl Med; 2019 Dec; 60(12):1698-1704. PubMed ID: 31076504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of [(18)F]FMISO stratified dose-escalation on local control in FaDu hSCC in nude mice.
    Schütze C; Bergmann R; Brüchner K; Mosch B; Yaromina A; Zips D; Hessel F; Krause M; Thames H; Kotzerke J; Steinbach J; Baumann M; Beuthien-Baumann B
    Radiother Oncol; 2014 Apr; 111(1):81-7. PubMed ID: 24636842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study.
    Lee NY; Mechalakos JG; Nehmeh S; Lin Z; Squire OD; Cai S; Chan K; Zanzonico PB; Greco C; Ling CC; Humm JL; Schöder H
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):2-13. PubMed ID: 17869020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The utility of multiparametric MRI to characterize hypoxic tumor subvolumes in comparison to FMISO PET/CT. Consequences for diagnosis and chemoradiation treatment planning in head and neck cancer.
    Wiedenmann N; Grosu AL; Büchert M; Rischke HC; Ruf J; Bielak L; Majerus L; Rühle A; Bamberg F; Baltas D; Hennig J; Mix M; Bock M; Nicolay NH
    Radiother Oncol; 2020 Sep; 150():128-135. PubMed ID: 32544609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overlap of highly FDG-avid and FMISO hypoxic tumor subvolumes in patients with head and neck cancer.
    Mönnich D; Thorwarth D; Leibfarth S; Pfannenberg C; Reischl G; Mauz PS; Nikolaou K; la Fougère C; Zips D; Welz S
    Acta Oncol; 2017 Nov; 56(11):1577-1582. PubMed ID: 28849721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spatial distribution of FMISO in head and neck squamous cell carcinomas during radio-chemotherapy and its correlation to pattern of failure.
    Zschaeck S; Haase R; Abolmaali N; Perrin R; Stützer K; Appold S; Steinbach J; Kotzerke J; Zips D; Richter C; Gudziol V; Krause M; Zöphel K; Baumann M
    Acta Oncol; 2015; 54(9):1355-63. PubMed ID: 26398663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two or four hour [¹⁸F]FMISO-PET in HNSCC. When is the contrast best?
    Abolmaali N; Haase R; Koch A; Zips D; Steinbach J; Baumann M; Kotzerke J; Zöphel K
    Nuklearmedizin; 2011; 50(1):22-7. PubMed ID: 21165537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Hypermetabolic and Hypoxic Volumes Delineated on [
    Thureau S; Modzelewski R; Bohn P; Hapdey S; Gouel P; Dubray B; Vera P
    Mol Imaging Biol; 2020 Jun; 22(3):764-771. PubMed ID: 31432388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative evaluation of oxygen metabolism in the intratumoral hypoxia:
    Watabe T; Kanai Y; Ikeda H; Horitsugi G; Matsunaga K; Kato H; Isohashi K; Abe K; Shimosegawa E; Hatazawa J
    EJNMMI Res; 2017 Dec; 7(1):16. PubMed ID: 28210996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.
    Okamoto S; Shiga T; Yasuda K; Ito YM; Magota K; Kasai K; Kuge Y; Shirato H; Tamaki N
    J Nucl Med; 2013 Feb; 54(2):201-7. PubMed ID: 23321456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of [18F]FMISO autoradiography and pimonidazole [corrected] immunohistochemistry in human head and neck carcinoma xenografts.
    Troost EG; Laverman P; Philippens ME; Lok J; van der Kogel AJ; Oyen WJ; Boerman OC; Kaanders JH; Bussink J
    Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1803-11. PubMed ID: 18421457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.